IRCT20170123032145N7
Not yet recruiting
未知
Acetylcysteine (NAC) augmentation in the treatment of symptoms and cognitive function among patients with obsessive-compulsive disorder A double-blind placebo-controlled, randomized clinical trial
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Obsessive-compulsive disorder.
- Sponsor
- Iran University of Medical Sciences
- Enrollment
- 44
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who meet DSM\-5 criterion for OCD and they achieve more than 21 for Yale\-Brown Obsessive Compulsive Scale are suitable for study.
- •They should be 18\-65 year old
- •They should sign the consent form
Exclusion Criteria
- •They should not be treated by any psychiatric interventions for last 6 weeks.
- •If they show any other important mental condition or suicidal thought, neurological deficit, will exclude from study.
- •They will be evaluated for cardiac, liver, kidney, pregnancy, lactation and mental retardation before entrance and any mentioned conditions will cause exclusion from study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Adjuvant N Acetylcysteine for Post Traumatuic Stress DisorderACTRN12618001784202Austin Health105
Recruiting
Phase 2
Effect of N-acetylcysteine as adjunct therapy versus placebo on clinical outcomes and serum levels of oxidative stress biomarkers in patients with systolic heart failureIRCT20120215009014N333Hamedan University of Medical Sciences80
Recruiting
Phase 3
Efficacy of N-Acetyl cysteine in patients with autism spectrum disorderAutism spectrum disorder.Childhood autismF84.0IRCT20190714044199N1Medical Science University of Mashhad66
Completed
Phase 3
The effectiveness of N-acetylcystein (NAC) on accelerating renal failer recoveryIRCT20190727044343N4Mazandaran University of Medical Sciences64
Completed
Phase 3
acetylcysteine in Unipolar depressionipolar depressionUnipolar depressionMental Health - DepressionACTRN12607000134426Mental Health Research Institute120